Eline van der Burg

3.0k citations

19 papers · 1.7k indexed · 1 hit paper · h-index 13

Co-authors: Jos Jonkers Patrick W.B. Derksen Mark J. O’Connor Michiel de Bruin Niall M.B. Martin Alan Lau Ariena Kersbergen Piet Borst
Topics: DNA Repair Mechanisms (6 papers)BRCA gene mutations in cancer (5 papers)PARP inhibition in cancer therapy (5 papers)
Cited by: Oncology Reproductive Medicine Cancer Research
Journals: Proceedings of the National Academy of Sciences Nature Communications Nature Genetics
Partner nations: Netherlands United Kingdom Germany

In The Last Decade

Eline van der Burg

18 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

2008 762 citations Sven Rottenberg, Janneke E. Jaspers et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Eline van der Burg

Since Specialization

Citations

This map shows the geographic impact of Eline van der Burg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eline van der Burg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eline van der Burg more than expected).

Fields of papers citing papers by Eline van der Burg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eline van der Burg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eline van der Burg. The network helps show where Eline van der Burg may publish in the future.

Co-authorship network of co-authors of Eline van der Burg

This figure shows the co-authorship network connecting the top 25 collaborators of Eline van der Burg. A scholar is included among the top collaborators of Eline van der Burg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eline van der Burg. Eline van der Burg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3 2025 ·Cancer Research ·(unknown),Jinhyuk Bhin,Eline van der Burg,Anne Paulien Drenth,(unknown),Catrin Lutz,(unknown),Ellen Wientjens,Sjoerd Klarenbeek,(unknown),(unknown),Stefano Annunziato,Natalie Proost,Bjørn Siteur,(unknown),Marieke van de Ven,(unknown),Shridar Ganesan,(unknown),Daniel Zingg,(unknown)	0
2	FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks 2023 ·Science Advances ·Abdelghani Mazouzi,Sarah C. Moser,Federico Abascal,Bram van den Broek,Martin Del Castillo Velasco‐Herrera,Ingrid van der Heijden,Maarten L. Hekkelman,Anne Paulien Drenth,Eline van der Burg,Lona J. Kroese,Kees Jalink,David J. Adams,Jos Jonkers,Thijn R. Brummelkamp	10
3	CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer 2023 ·Nature Communications ·Julia M. Houthuijzen,Roebi de Bruijn,Eline van der Burg,Anne Paulien Drenth,Ellen Wientjens,(unknown),(unknown),Chiara Svetlana Brambillasca,Emilia M. Pulver,Marja Nieuwland,Iris de Rink,(unknown),Sjoerd Klarenbeek,Ron Kerkhoven,Valerie G. Brunton,Colinda L. G. J. Scheele,Mirjam C. Boelens,Jos Jonkers	63
4	Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms 2020 ·Cancer Research ·Koen Schipper,Anne Paulien Drenth,Eline van der Burg,(unknown),Sjoerd Klarenbeek,Micha Nethe,Jos Jonkers	7
5	Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer 2019 ·Nature Communications ·Stefano Annunziato,Julian R. de Ruiter,Linda Henneman,Chiara Svetlana Brambillasca,Catrin Lutz,François Vaillant,Federica Ferrante,Anne Paulien Drenth,Eline van der Burg,Bjørn Siteur,(unknown),Roebi de Bruijn,Martine H. van Miltenburg,Ivo J. Huijbers,Marieke van de Ven,Jane E. Visvader,Geoffrey J. Lindeman,Lodewyk F.A. Wessels,Jos Jonkers	54
6	Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin 2019 ·Nature Communications ·Koen Schipper,Daniëlle Seinstra,Anne Paulien Drenth,Eline van der Burg,(unknown),Arnoud Sonnenberg,Jacco van Rheenen,Micha Nethe,Jos Jonkers	23
7	TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development 2019 ·Genes & Development ·(unknown),Anne Paulien Drenth,Eline van der Burg,Roebi de Bruijn,Colin E.J. Pritchard,Ivo J. Huijbers,Wilbert Zwart,Jos Jonkers	37
8	BRCA1‐associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling 2018 ·The Journal of Pathology ·Marieke van de Ven,Xiaoling Liu,Eline van der Burg,Sjoerd Klarenbeek,Xanthippi Alexi,Wilbert Zwart,Fred A. Dijcks,Peter Bouwman,Jos Jonkers	9
9	Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma 2017 ·Nature Genetics ·Sjors M. Kas,Julian R. de Ruiter,Koen Schipper,Stefano Annunziato,Eva Schut,Sjoerd Klarenbeek,Anne Paulien Drenth,Eline van der Burg,Christiaan Klijn,Jelle J. ten Hoeve,David J. Adams,Marco J. Koudijs,Jelle Wesseling,Micha Nethe,Lodewyk F.A. Wessels,Jos Jonkers	55
10	PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma 2016 ·Cell Reports ·Mirjam C. Boelens,Micha Nethe,Sjoerd Klarenbeek,Julian R. de Ruiter,Eva Schut,Nicola Bonzanni,Amber L. Zeeman,Ellen Wientjens,Eline van der Burg,Lodewyk F.A. Wessels,Renée van Amerongen,Jos Jonkers	37
11	EZH2 inhibition sensitizes BRCA1-deficient breast tumors to the PI3K inhibitor BKM120 2016 ·Geburtshilfe und Frauenheilkunde ·Julian Puppe,Marieke van de Ven,Eline van der Burg,Ute Boon,Olaf van Tellingen,Peter Bouwman,Peter Mallmann,Rita K. Schmutzler,Maarten van Lohuizen,(unknown)	1
12	Prophylactic window therapy with the clinical poly(ADP‐ribose) polymerase inhibitor olaparib delays BRCA1‐deficient mammary tumour formation in mice 2016 ·The Journal of Pathology ·Marieke van de Ven,Eline van der Burg,Hanneke van der Gulden,Sjoerd Klarenbeek,Peter Bouwman,Jos Jonkers	3
13	Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation 2014 ·International Journal of Cancer ·Floris H. Groenendijk,Wouter W. Mellema,Eline van der Burg,Eva Schut,Michael Hauptmann,Hugo M. Horlings,Stefan M. Willems,Michel M. van den Heuvel,Jos Jonkers,Egbert F. Smit,René Bernards	61
14	Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice 2011 ·Disease Models & Mechanisms ·Patrick W.B. Derksen,Tanya M. Braumuller,Eline van der Burg,Marten Hornsveld,Elly Mesman,Jelle Wesseling,Paul Krimpenfort,Jos Jonkers	101
15	Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan 2010 ·Cancer Research ·Serge A.L. Zander,Ariena Kersbergen,Eline van der Burg,(unknown),Olaf van Tellingen,(unknown),Janneke E. Jaspers,Marina Pajic,Anders O.H. Nygren,Jos Jonkers,Piet Borst,Sven Rottenberg	66
16	A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors 2009 ·Clinical Cancer Research ·Bastiaan Evers,Eva Schut,Eline van der Burg,Tanya M. Braumuller,David A. Egan,Henne Holstege,Pauline Edser,David J. Adams,Richard Wade‐Martins,Peter Bouwman,Jos Jonkers	66
17	Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer 2009 ·Cancer Research ·Marina Pajic,Jayasree K. Iyer,Ariena Kersbergen,Eline van der Burg,Anders O.H. Nygren,Jos Jonkers,Piet Borst,Sven Rottenberg	77
18	High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsbreakdown → 2008 ·Proceedings of the National Academy of Sciences ·Sven Rottenberg,Janneke E. Jaspers,Ariena Kersbergen,Eline van der Burg,Anders O.H. Nygren,Serge A.L. Zander,Patrick W.B. Derksen,Michiel de Bruin,John Zevenhoven,Alan Lau,(unknown),Aaron Cranston,Mark J. O’Connor,Niall M.B. Martin,Piet Borst,Jos Jonkers	762
19	Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin 2008 ·Clinical Cancer Research ·Bastiaan Evers,Rinske Drost,Eva Schut,Michiel de Bruin,Eline van der Burg,Patrick W.B. Derksen,Henne Holstege,Xiaoling Liu,Ellen van Drunen,H. Berna Beverloo,Graeme C.M. Smith,Niall M.B. Martin,Alan Lau,Mark J. O’Connor,Jos Jonkers	259

About Eline van der Burg

Eline van der Burg is a scholar working on Oncology, Molecular Biology and Cancer Research, having authored 19 papers that have together received 1.7k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (6 papers), BRCA gene mutations in cancer (5 papers) and PARP inhibition in cancer therapy (5 papers). The work is most often cited by research in Oncology (1.3k citations), Reproductive Medicine (152 citations) and Cancer Research (262 citations). Eline van der Burg has collaborated with scholars based in Netherlands, United Kingdom and Germany. Frequent co-authors include Jos Jonkers, Patrick W.B. Derksen, Mark J. O’Connor, Michiel de Bruin, Niall M.B. Martin, Alan Lau, Ariena Kersbergen, Piet Borst, Anders O.H. Nygren and Sven Rottenberg. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Communications and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact